Veru is trading 15.02% up now at $2.68 after fiscal Q3 2026 results showed a narrower-than-expected $0.30 EPS loss and continued progress in its obesity program.
- Phase 2b PLATEAU fully enrolled 239 patients, exceeding its 200-patient target.
- Interim data is expected in the first quarter of 2027.
- Veru is prioritizing clinical development following its strategic shift to a pure-play biotech model.